TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05056818

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records and past imaging examinations
Study: NCT01927848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosehip
Description: Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
Study: NCT01751425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study: NCT00406094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01295229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic Roux-en-Y gastric bypass (RYGB) procedure
Description: The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
Study: NCT04180774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tag-7 gene modified inactivated tumor cells
Description: Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tag-7 gene modified inactivated tumor cells
Description: Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tag-7 gene modified inactivated tumor cells
Description: Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tag-7 gene modified inactivated tumor cells
Description: Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
Study: NCT02578771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZuraPrep with 70% IPA
Description: Apply topically
Study: NCT01358253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-asparaginase
Description: Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Description: Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
Study: NCT01105182

Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation
Description: Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
Study: NCT00108550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Inert placebo
Description: Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
Study: NCT00460850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40KD) [PEGASYS]
Description: 180 micrograms sc weekly for 48 weeks
Study: NCT02578771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep with 70% IPA
Description: Apply topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZuraPrep without 70% IPA
Description: Apply topically. 0% IPA
Study: NCT00490555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Testosterone gel 10 g
Study: NCT02578771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep without 70% IPA
Description: Apply topically. 0% IPA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep CHG/IPA Teal Tint
Description: Apply topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChloraPrep CHG/IPA Teal Tint
Description: Apply topically
Study: NCT00490555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: dutasteride 0.5 mg orally
Study: NCT02578771

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Apply topically
Study: NCT01751425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study: NCT00490555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medroxyprogesterone (DMPA)
Description: 300 mg DMPA injection on Day 0 IM (into the muscle)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Testosterone gel
Description: Place gel applied daily for 12 weeks
Study: NCT02578771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Apply topically
Study: NCT04359329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
Study: NCT01241773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: One 400 mg tablet twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + raltegravir
Description: Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Two 75 mg capsules once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + efavirenz
Description: Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
Study: NCT02315950

Intervention type: OTHER
Group type: OTHER
Intervention: Botulinum toxin and cineMRI-UDS
Description: The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
Study: NCT06564051

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT01673919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 104 weeks
Study: NCT02790736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive pill
Study: NCT04854473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exero Medical Leak Detection System
Description: the Exero Leak Detection System components used in this study are:~* Smart drain - a surgical drain with added sensing electrodes~* Transceiver /Recording Unit (TRU) - a wearable placed outside the body on intact skin and is connected to the implanted electrodes. The unit also acts as a wireless connection to the Monitoring Subsystem.~* Monitoring Subsystem - a tablet or a computer connected wirelessly to the transceiver providing logging, applying analysis algorithms on the logged signals and providing indication/alerts to the medical staff derived from the signals recorded by the electrodes.
Study: NCT04023058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral surgery
Description: Guidelines approved mitral surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral surgery
Description: Guidelines approved mitral surgery
Study: NCT01241773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Two 75 mg capsules once daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: One 600 mg tablet once daily for 14 days
Study: NCT04023058

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mitral surgery
Description: Guidelines approved mitral surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mitral surgery
Description: Guidelines approved mitral surgery
Study: NCT01893086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LH alone
Description: LH, laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LH with opportunistic salpingectomy
Description: LH, laparoscopic hysterectomy
Study: NCT03287986

Intervention type: OTHER
Intervention: MRI
Description: Structural and functional sequences

Intervention type: OTHER
Intervention: MRI
Description: Structural and functional sequences

Intervention type: OTHER
Intervention: MRI
Description: Structural and functional sequences
Study: NCT00370084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: oral, three times daily
Study: NCT04753476

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of Secretome-MSCs
Description: Injection of Hypoxic Secretome-MSCs intramuscular (deltoideus) :~Day 1: 1 cc every 12 hours~Day 2: 1 cc every 12 hours~Day 3: 1 cc every 12 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Standard treatment of Covid-19
Description: Patients will be given Standard treatment of Covid-19 which accordance with National protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment of Covid-19
Description: Patients will be given Standard treatment of Covid-19 which accordance with National protocol
Study: NCT00551044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Bicalutamide 150mg once daily, oral administration, for 12 months
Study: NCT00978471

Intervention type: DRUG
Group type: OTHER
Intervention: Thiotepa
Description: Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
Study: NCT00490555

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dutasteride
Description: placebo pill for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo dutasteride
Description: placebo pill for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DMPA
Description: placebo DMPA injection Once
Study: NCT03782038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCD
Description: Micro coring skin removal with automated coring device
Study: NCT01385371

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass (Phleum pratense) pollen allergen extract
Description: One dissolving tablet sublingually once daily

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SCH 697243
Description: One dissolving tablet sublingually once daily
Study: NCT00915356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
Study: NCT04253912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP-245
Description: 2% Povidone-Iodine Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel (no Povidone-Iodine)
Description: Placebo Gel (no Povidone-Iodine)
Study: NCT00568503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX028

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium bromide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX028
Study: NCT03537885

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: A cap is placed on the head with sensors to detect brain activity during the intervention.
Study: NCT01580943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?).
Study: NCT01649427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf
Description: Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
Study: NCT02623478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study: NCT02644031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mtwo rotary system
Description: post-treatment pain after using mtwo rotary system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: safe-sider rotary system
Description: post-treatment pain after using safe-sider rotary system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand files
Description: post-treatment pain after using hand files
Study: NCT01841307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Study: NCT00370084

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, three times daily
Study: NCT00213525

Intervention type: OTHER
Intervention: Questionnary for environmental factors research
Description: Questionnary for environmental factors research
Study: NCT04645420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global gene expression profiles obtained from synovial biopsies.
Description: Global gene expression profiles obtained from synovial biopsies before and after 24 weeks of treatment with the drug in each patient.
Study: NCT04627337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG
Description: Probiotic yeast in capsules

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice following a low fermentation diet
Description: Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary advice following a low fermentation diet
Description: Medical advice was delivered to patients to follow a low fermentation diet. A list of food and beverages to avoid was delivered along with specified instructions provided by a health professional
Study: NCT00546650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan succinate
Description: NP101 iontophoretic transdermal system

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan succinate
Description: NP101 iontophoretic transdermal system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan succinate
Description: oral, subcutaneous, and intranasal formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan succinate
Description: oral, subcutaneous, and intranasal formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan succinate
Description: oral, subcutaneous, and intranasal formulations
Study: NCT04102956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kallikrein
Description: HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
Study: NCT00386607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 320 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 320 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: Hydrochlorothiazide (HCTZ) 12.5-25 mg
Study: NCT00853034

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FOS-IN
Description: prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AXOS
Description: arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening
Study: NCT04105283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tc99m-MAA
Description: Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
Study: NCT00673946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: True saturation values displayed
Description: Physicians will be presented with real saturations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altered saturation values displayed.
Description: Physicians will be presented with saturation measurements three percentage points above the true values.
Study: NCT03700125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECMO resuscitation
Description: Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
Study: NCT02522962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GroupCoreSIT
Description: Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
Study: NCT02290327

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Proton pump inhibitor
Study: NCT04266860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental - Test Results and Education
Description: First, these providers will receive educational materials (e.g. a slide deck, mock test result and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the DxTerity test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the DxTerity test at the clinically-appropriate point in each case.
Study: NCT03278080

Intervention type: OTHER
Group type: OTHER
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement